TRLS-06. A Phase 1–2 clinical trial of EO1001 (APL-122), a novel irreversible pan-ErbB inhibitor with promising brain penetration

CNS metastases are a prominent driver of cancer morbidity and mortality, especially as targeted therapies have improved systemic outcomes. Mutations in the ErbB/HER kinase family are known oncodrivers in many cancers. Extensive cross-talk among ErbB/HER receptors suggests that inhibition of multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Frentzas, Sophia, Richardson, Gary, Bacha, Jeffrey, Kanekal, Sarath, Sankar, Neil, Shen, Wang, Redkar, Sanjeev, Lai, Chinglin, Yu, Peony, Nisbet, Ian, Skoff, Kathy, Wheeler, Helen, Pedersen, Harry, Zhong, Wang Zhen, Brown, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351242/
http://dx.doi.org/10.1093/noajnl/vdab071.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351242/
http://dx.doi.org/10.1093/noajnl/vdab071.024

Ejemplares similares